<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Humacyte, Inc.</title><link>https://investorshangout.com/Humacyte-Inc-HUMA-94355/</link><description><![CDATA[Humacyte, Inc. (HUMA)]]></description><language>en-us</language><pubDate>Wed, 02 Sep 2026 09:29:20 GMT</pubDate><copyright>Copyright InvestorsHangout.com</copyright><atom:link href="https://investorshangout.com/Humacyte-Inc-HUMA-94355/" rel="self" type="application/rss+xml"/><item><title>Rubraquercus: 1. Assigned Priority Review Designation by Secretary of Defense under Law 115-92 which is used for m</title><link>https://investorshangout.com/post/view?id=6737841</link><guid>https://investorshangout.com/post/view?id=6737841</guid><description><![CDATA[Rubraquercus
]]></description><pubDate>Thu, 02 Jan 2025 13:14:59 GMT</pubDate></item><item><title>Rubraquercus:  In 2010, the HUMA co-founder and CEO, Dr. Laura Niklason and her colleagues were able to successful</title><link>https://investorshangout.com/post/view?id=6737840</link><guid>https://investorshangout.com/post/view?id=6737840</guid><description><![CDATA[Rubraquercus
]]></description><pubDate>Thu, 02 Jan 2025 12:29:27 GMT</pubDate></item><item><title>znewcar1: HUMA 26% v3,4M c4.40 f103M H4.53 ML3.2</title><link>https://investorshangout.com/post/view?id=6452995</link><guid>https://investorshangout.com/post/view?id=6452995</guid><description><![CDATA[znewcar1
]]></description><pubDate>Fri, 12 Aug 2022 02:04:10 GMT</pubDate></item></channel></rss>